Shionogi & Co.,Ltd.
Shionogi Continues Rare Disease Expansion With Planned Acquisition of IntraBio Inc.
Filed with TSE ·
6ix hasn’t read this filing yet.
View original source (TDnet)Company analysis
Earlier from Shionogi &
- COVGOZE for Intramuscular Injection (JN.1-adapted), Recombinant Protein COVID-19 Vaccine, Receives Partial Change Approval in Japan
- Shionogi Announces U.S. Government Procurement of Fetroja through BARDA's Project BioShield to Support National Preparedness for Drug-Resistant Bacterial Threats
- Consolidated Financial Results for the First Quarter of Fiscal Year 2026 (IFRS)
- Shionogi Recognizes the Four-Year Anniversary of RADICAVA ORS® (edaravone) for Treatment of ALS